白藜芦醇通过抑制蛋白酶体蛋白酶下调脓毒症生物标志物
该研究在纯化的人血单核细胞蛋白酶体和CD14单核细胞中比较白藜芦醇与LMP7特异性抑制剂ONX-0914对蛋白酶体活性及LPS诱导炎症标志物的影响。白藜芦醇(0-100 μM)抑制全部三种蛋白酶活性(以LMP7为主),ONX-0914对LMP7更具选择性和效力。两者均显著抑制LPS诱导的VCAM-1、ICAM1、CRP、resistin及蛋白酶体LMP亚基表达;白藜芦醇使CD14单核细胞pIκBα蓄积,减少NF-κB转位。作者认为白藜芦醇可用于遏制脓毒症等疾病状态的炎症。
要点
- 在纯化人血单核细胞蛋白酶体中,白藜芦醇(0-100 μM)抑制全部三种蛋白酶活性,以LMP7为主。
- 在CD14单核细胞中,白藜芦醇与ONX-0914均显著抑制LPS诱导的VCAM-1、ICAM1、CRP、resistin及蛋白酶体LMP亚基表达。
- 白藜芦醇使CD14单核细胞pIκBα蓄积(单用及与LPS联用),减少NF-κB转位,降低LPS诱导的炎症因子表达。
- 白藜芦醇对三种蛋白酶活性抑制效力低于ONX-0914,但按自噬检测试剂盒观察对人单核细胞毒性更低。
- 作者认为白藜芦醇可用于遏制脓毒症及其他疾病状态的炎症。
适用人群与场景
- 体外研究:人血单核细胞及纯化的人血单核细胞蛋白酶体,未涉及患者人群或临床场景。
研究设计与关键结果
- 研究类型为体外细胞实验;在白藜芦醇(0-100 μM)作用下,纯化人血单核细胞蛋白酶体的三种蛋白酶活性均被抑制,以LMP7为主;ONX-0914对LMP7活性更具选择性和效力。
- 细胞基发光检测中白藜芦醇同样抑制全部三种蛋白酶活性。
- 白藜芦醇与ONX-0914均显著抑制CD14单核细胞中LPS诱导的VCAM-1、ICAM1、CRP、resistin及蛋白酶体LMP亚基表达。
- 白藜芦醇单用及与LPS联用均使CD14单核细胞pIκBα蓄积。
- 按自噬检测试剂盒观察,白藜芦醇对人单核细胞毒性低于ONX-0914。
证据类型、等级与局限
- 证据类型:体外细胞实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文为体外细胞实验,作者认为白藜芦醇可用于遏制脓毒症及其他疾病状态的炎症;未提供临床用药剂量、途径或疗程。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Lipopolysaccharide (LPS) is the main agonist of gram-negative bacteria and initiates inflammation. We recently reported that plasmas from sepsis patients revealed increased levels of following group of biomarkers; VCAM-1, ICAM1, CRP, resistin, and proteasome LMP subunits. Our objective here was to compare effects of resveratrol (shown to be a nonspecific proteasome inhibitor by us) and a known LMP7 inhibitor (ONX-0914, specific inhibitor) on proteasome's activities, as well as on inflammatory markers mentioned above in human blood monocytes. Using fluorescence-based assays on blood monocytes purified proteasomes, resveratrol (0-100 μM) inhibited all three protease activities, predominantly LMP7. Similarly, resveratrol inhibited all three protease activities using cell-based luminescence assay. In contrast, ONX-0914 was more selective and potent for LMP7 activity. Resveratrol and ONX-0914, both significantly inhibited expression of LPS-induced biomarkers mentioned above in CD14 monocytes. Moreover, resveratrol itself, as well as in combination with LPS, accumulated pIκBα in CD14 monocytes. Collectively, our data suggest that resveratrol is a less potent inhibitor of all three; CT-like (predominantly LMP7), T-like and PA protease activities and is less toxic to human monocytes than ONX-0914 (a selector inhibitor of only LMP7) as observed by an autophagy detection kit. Also, resveratrol reduces LPS-induced inflammatory cytokine expression by decreasing the translocation of NF-κB due to an increase in inhibitor pIκBα. Therefore, resveratrol can be used to curb inflammation in diseased states like sepsis and other disorders.
参考来源
- Silswal N, Reddy NS, Qureshi AA, et al. Resveratrol Downregulates Biomarkers of Sepsis Via Inhibition of Proteasome's Proteases. Shock. 2018. PMID: 29240645. doi:10.1097/SHK.0000000000001080
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。